Cargando…

Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience

OBJECTIVES: To highlight the clinical benefit, efficacy, and safety of zoledronic acid (ZA) therapy in children and adolescents with primary and secondary osteoporosis. METHODS: This is a retrospective observational study of 131 children and adolescents visiting the Pediatric Endocrine Clinic at Kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Agha, Abdulmoein E., Hayatalhazmi, Rahaf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673368/
https://www.ncbi.nlm.nih.gov/pubmed/26593164
http://dx.doi.org/10.15537/smj.2015.11.12590
_version_ 1782404726738911232
author Al-Agha, Abdulmoein E.
Hayatalhazmi, Rahaf S.
author_facet Al-Agha, Abdulmoein E.
Hayatalhazmi, Rahaf S.
author_sort Al-Agha, Abdulmoein E.
collection PubMed
description OBJECTIVES: To highlight the clinical benefit, efficacy, and safety of zoledronic acid (ZA) therapy in children and adolescents with primary and secondary osteoporosis. METHODS: This is a retrospective observational study of 131 children and adolescents visiting the Pediatric Endocrine Clinic at King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia, between January 2002 and January 2015. Clinical and laboratory data were collected for each patient and adverse events were evaluated. RESULTS: The mean patient age was 11.43 years. There was a significant decrease in the number of fractures after ZA treatment for primary osteoporosis (p=0.000) and in secondary osteoporosis (p=0.005). There was a significant decrease in both osteocalcin (p=0.001) and C-terminal telopeptide (p=0.003) in patients with primary osteoporosis, as well as osteocalcin (p=0.003) and C-terminal telopeptide (p=0.008) in patients with secondary osteoporosis after treatment. CONCLUSION: The use of ZA in children and adolescent appears to have favorable effects on fracture rate and quality of life, including pain and mobility in symptomatic individuals. Intravenous ZA is comparable to other bisphosphonate agents in its efficacy and safety and features a more convenient infusion protocol with no documented long-term complications, thus, we advise its use in pediatric population.
format Online
Article
Text
id pubmed-4673368
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-46733682015-12-10 Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience Al-Agha, Abdulmoein E. Hayatalhazmi, Rahaf S. Saudi Med J Original Article OBJECTIVES: To highlight the clinical benefit, efficacy, and safety of zoledronic acid (ZA) therapy in children and adolescents with primary and secondary osteoporosis. METHODS: This is a retrospective observational study of 131 children and adolescents visiting the Pediatric Endocrine Clinic at King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia, between January 2002 and January 2015. Clinical and laboratory data were collected for each patient and adverse events were evaluated. RESULTS: The mean patient age was 11.43 years. There was a significant decrease in the number of fractures after ZA treatment for primary osteoporosis (p=0.000) and in secondary osteoporosis (p=0.005). There was a significant decrease in both osteocalcin (p=0.001) and C-terminal telopeptide (p=0.003) in patients with primary osteoporosis, as well as osteocalcin (p=0.003) and C-terminal telopeptide (p=0.008) in patients with secondary osteoporosis after treatment. CONCLUSION: The use of ZA in children and adolescent appears to have favorable effects on fracture rate and quality of life, including pain and mobility in symptomatic individuals. Intravenous ZA is comparable to other bisphosphonate agents in its efficacy and safety and features a more convenient infusion protocol with no documented long-term complications, thus, we advise its use in pediatric population. Saudi Medical Journal 2015-11 /pmc/articles/PMC4673368/ /pubmed/26593164 http://dx.doi.org/10.15537/smj.2015.11.12590 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Al-Agha, Abdulmoein E.
Hayatalhazmi, Rahaf S.
Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title_full Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title_fullStr Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title_full_unstemmed Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title_short Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia: A 13-year experience
title_sort osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in western saudi arabia: a 13-year experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673368/
https://www.ncbi.nlm.nih.gov/pubmed/26593164
http://dx.doi.org/10.15537/smj.2015.11.12590
work_keys_str_mv AT alaghaabdulmoeine osteoporosistreatmentwithzoledronicacidinpediatricpopulationatauniversityhospitalinwesternsaudiarabiaa13yearexperience
AT hayatalhazmirahafs osteoporosistreatmentwithzoledronicacidinpediatricpopulationatauniversityhospitalinwesternsaudiarabiaa13yearexperience